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ABSTRACT: A versatile strategy for C7-selective boronation of
tryptophans, tryptamines, and 3-alkylindoles by way of a single-pot
C2/C7-diboronation−C2-protodeboronation sequence is described.
The combination of a mild iridium-catalyzed C2/C7-diboronation
followed by an in situ palladium-catalyzed C2-protodeboronation
allows eﬃcient entry to valuable C7-boroindoles that enable further
C7-derivatization. The versatility of the chemistry is highlighted by the
gram-scale synthesis of C7-boronated N-Boc-L-tryptophan methyl
ester and the rapid synthesis of C7-halo, C7-hydroxy, and C7-aryl
tryptophan derivatives.
Indole derivatives are prevalent in many natural products andpharmaceutical compounds, often as complex tryptophan-
and tryptamine-derived substructures.1 The demand for such
diversely substituted indolic structures has led to the develop-
ment of ever more eﬃcient and direct methods for their
synthesis, none more so than in the nascent ﬁeld of C−H
functionalization.2−6 Within this realm, some inventive and
practical chemistry has been developed to functionalize
diﬀerent positions around the indole ring, mainly through the
innate reactivity of the C2,3 C3,4 and C55 sites and to a lesser
extent C4 and C6.6 The growing number of structurally and
biologically fascinating natural and unnatural products bearing
an indole substituent at C7 (i.e., 1−6, Figure 1) has generated
further interest in methods that expedite functionalization at
this position.7−11 Many such targets, including chloropeptin I,8
the teleocidins (i.e., 1),9 the indole-glyoxamide class of HIV-1
attachment inhibitors (i.e., 4),10 and the 3-aroylindole isosteres
of combretastatin (6),11 have been shown to exhibit potent
biological activities.
Selective C7 indole functionalization has proven particularly
challenging in the case of tryptamine and tryptophan
derivatives. In the latter case, the most commonly used
strategies target 7-bromotryptophan, which requires either
enzymatic processes12 or a multistep synthesis from 7-
bromoindole.9g,13 Our group’s continuing goal to unearth and
expand new avenues for the elaboration of complex indole-
derived natural products spurred our interest in addressing this
challenge.14 Herein we wish to report a practical and versatile
one-pot method for C7 boronation of C3-substituted indoles,
including tryptophans and tryptamines, in turn permitting rapid
C7 indole functionalization via the corresponding C7-
boronated products.
In the past decade, important inroads into C7 indole
functionalization have been made through metal-catalyzed
arene and heteroarene C−H boronations.15,16 Of particular
relevance to us were the reports into iridium-catalyzed indole
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Figure 1. Representative biologically active C7-substituted indoles.
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boronations,17 which Smith17c and later James17e showed
would proceed selectively at C7 in the presence of C2
substituents to block the inherently greater azole reactivity. An
interesting substrate in Smith’s study was 2-trimethylsilyl
indole, which was boronated in 76% yield under their
conditions, with subsequent desilylation aﬀording a 7-
boroindole in 88% yield.17c Then in 2010, Hartwig’s group
utilized a variant of their hydrosilyl-directed ortho-boronation
chemistry18,19 as a platform for the ﬁrst truly C7-selective
boronation reaction. Their three-step methodology exploited
the N1-appended silane directing group on indole 8 to enable
regioselective boronation to 7-boroindole 9 (Scheme 1).18c
Inspired by these studies, we sought to develop a more
streamlined process for direct conversion of tryptamines and
tryptophans to the corresponding C7-boronated indoles. By
taking advantage of the more nucleophilic/basic C2 position of
these C3-substituted indoles (i.e., 11), we have now been able
to fashion a two-step, one-pot procedure for C7-selective
boronation. This methodology provides an expedient means for
C7 derivatization of these compounds on a large scale through
direct activation of unfunctionalized tryptamines and trypto-
phans. The premise behind this diboronation/protodeborona-
tion sequence was our recognition of the high propensity of
ﬁve-membered heterocycles to readily undergo C2 proto-
deboronation.20−24 Indeed, this oft-maligned side reaction of
Suzuki−Miyaura cross couplings involving C2-boronated
indoles,14a,g,21a−h furans,22 and thiophenes23 has been exten-
sively studied in acidic media.24 Thus, a synthetic operation was
envisioned involving iridium-catalyzed boronation of C3-
substituted indole 11, ﬁrst at C2,17 and then C7, to give
diboronated indole 12, followed by acidic workup to induce
ipso-protonation, rearomatization, and cleavage of the carbon−
boron bond to aﬀord 7-boroindole 13 (Scheme 2).
During initial investigations into the diboronation of
tryptamine, introduction of a mesitylsulfonyl on the amine
side chain helped avoid some of the undesired aryl boronations
that we ﬁrst observed when utilizing phthalimido,25 benzene-
sulfonyl, or p-nitrobenzenesulfonyl protective groups. Further-
more, the use of Nα-methylated mesitylsulfonamide 11a
(Scheme 3) would also permit direct mapping of a C7-
derivatized tryptamine onto many of the biologically interesting
cyclotryptamine natural products that carry an Nα-methyl
substituent.26 As conﬁrmation of the order of ring boronation,
exposure of tryptamine 11a to 1 equiv of boronating reagent, in
conjunction with 2 mol % [Ir(cod)OMe]2 and 4 mol % 4′-di-
tert-butyl-2,2′-bipyridine (dtbpy), delivered the C2-boronated
product 14 in 68% yield (Scheme 3). Under these conditions, a
minor amount (<10%) of the 2,7-diboronated product 12a was
also generated, an observation previously noted by James and
co-workers in their microwave-assisted C2-boronation of N-
Boc-tryptophan methyl ester.17e In our case, inclusion of a
second equivalent of bis(pinacolato)diboron under the same
conditions (see (a), Scheme 3) led to substantial decom-
position. Attempts to remedy this by extending the reaction
time to 16 h at ambient temperature however only increased
slightly the conversion to 2,7-diborotryptamine 12a, with 2-
borotryptamine 14 still the major product. While switching to
n-hexane as solvent and using higher catalyst loadings improved
substantially the conversion of precursor 11a to the desired
product 12a (>75% by NMR), these more forcing conditions
led to only 27% yield of the desired product being isolated.
After further optimization, tetrahydrofuran (see conditions (b),
Scheme 3) proved to be the optimal solvent for full
incorporation of the second boron at C7, delivering tryptamine
12a in 80% yield. At slightly elevated reaction temperatures
and/or prolonged times, triboronated tryptamine, resulting
from further boronation at C5 of diborotryptamine 12a, was
also observed in minor amounts. Our regiochemical assignment
of the two newly formed carbon−boron bonds in compound
12a was conﬁrmed by 1D NOE diﬀerence experiments
(Scheme 3).
Guided by the wealth of literature on acid-promoted
protodemetalations of heteroarenes,21n,22e,23b,24,27,28 we were
then able to extend our diboronation procedure to one that also
included in situ C2 protodeboronation. After initial success in
converting diboroindole 12a into 7-boroindole 13a by simple
Scheme 1. Silane-Directed C7 Boronation of Indoles
Scheme 2. Planned Synthesis of C7-Borotryptamines
Scheme 3. Initial Screening of C2/C7 Boronationsa
aConditions: (a) [Ir(cod)OMe]2 (2 mol %), 4,4′-di-tert-butyl-2,2′-
bipyridine (4 mol %), (Bpin)2 (1 equiv), CH2Cl2, 60 °C, 3 h, 68%; (b)
[Ir(cod)OMe]2 (2 mol %), 4,4′-di-tert-butyl-2,2′-bipyridine (4 mol %),
(Bpin)2 (2 equiv), THF, 65 °C, 20 h, 80%; (c) TFA (10 equiv),
CH2Cl2, 23 °C, 15 min, 81%.
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exposure to triﬂuoroacetic acid (i.e., conditions (c) in Scheme
3),28 we then explored using the same conditions once the C2/
C7 diboronation of tryptamine 11a (i.e., conditions (a) in
Scheme 3) had been allowed to run its course. To minimize bis-
protodeboronation and recovery of starting material 11a, the
reaction mixture was ﬁrst diluted with dichloromethane prior to
addition of triﬂuoroacetic acid. Gratifyingly, addition of an
equal volume (relative to tetrahydrofuran) of triﬂuoroacetic
acid at 0 °C to a 3:2 (v:v) dichloromethane−THF solution
aﬀorded 7-borotryptamine 13a in 60% yield (entry 1, Table 1).
We next focused on applying our one-pot diboronation/
protodeboronation regimen to other valuable C3-substituted
indole derivatives (Table 1).29 We were pleased to conﬁrm that
changing the tryptamine protective group to a methyl
carbamate in substrate 11b was in no way detrimental to the
outcome of our reaction and improved our yield of 7-
borotryptamine to 66% for carbamate 13b (entry 2). We also
found that the time and temperature for initial diboronation
could be tempered without needing to increase the
stoichiometry of reagents. Apart from tryptamine 11a (entry
1, Table 1), a temperature of 60 °C and reaction time of 4−7 h
was found to be ideal for most of the diboronations (entries 2−
5, Table 1).30,31 The applicability of this protocol to other 3-
substituted indoles was also highlighted by the eﬃcient
conversion of indoles 11c and 11e to 7-boroindoles 13c and
13e, respectively (entries 3 and 5). In the latter case (entry 5),
the presence of a primary alcohol did not impede diboronation
of tryptophol 11e from proceeding just as eﬃciently as was
observed with 3-methylindole 13c, as evidenced by the 63%
yield for 7-borotryptophol 13e. Importantly, selective borona-
tion of tryptophan derivative 11d to the corresponding 7-
borotryptophan 13d was achieved in 84% yield (entry 4).
It should be noted that in all these examples the only other
side product recovered from the two-step sequence was a
minor amount of starting material 11a−e (<5%). The fact that
traces of starting material 11a were also observed upon
converting pure 2,7-diborotryptamine 12a to 7-borotryptamine
13a suggested that the conditions in the second step may cause
unwanted C7 protodeboronation. This led us to focus our
eﬀorts on further optimization of the C2 protodeboronation
step. More speciﬁcally, to make our process more amenable to
Nα-Boc-protected tryptophans,17d,e it was deemed necessary to
move toward a milder protodeboronation that obviated the use
of triﬂuoroacetic acid.
The diboronation of N-Boc-tryptophan methyl ester 11f
proceeded smoothly under the optimal iridium-catalyzed
conditions (Scheme 4). Diborotryptophan 12f could be
isolated by concentration of the reaction mixture and puriﬁed
by ﬂash column chromatography in ca. 88% yield.32 After
investigation of a range of basic and acidic conditions, we found
that C2 protodeboronation of 12f could be eﬃciently
promoted by a catalytic amount of palladium(II) acetate in
acetic acid.21a−h The optimal temperature for this step of 30 °C
delivered 13f in 85% yield (2.0 mmol scale) from tryptophan
12f. Further still, the dried crude mixture from the diboronation
of 11f could also be subjected to these same protodeboronation
conditions to provide 13f in 73% yield on gram scale, once
more rendering this a two-step, one-pot method (Scheme 4).
Compared to the conditions used in Table 1, this alternative
procedure gave similar yields of 58% and 72%, respectively, for
the C7 boronation of indole 11c (entry 3, Table 1) and
tryptophan 11d (entry 4, Table 1).
The broader utility of this one-pot boronation protocol for
the rapid synthesis of 7-substituted tryptamines and trypto-
phans is highlighted by the facile conversion of 7-boroindole 13
to a variety of derivatives (Scheme 5). The 7-borotryptophan
Table 1. Rapid Synthesis of C7-Boronated 3-Substituted
Indole Derivatives
aIsolated yield after puriﬁcation. bBoronation conducted at 80 °C.
cSecond step: Pd(OAc)2 (5 mol %), AcOH, 30 °C.
dGram-scale
reaction.
Scheme 4. Optimized C7 Boronation of N-Boc-tryptophan
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13d was converted to the corresponding 7-chloro-, 7-bromo-,
and 7-iodotryptophan derivatives 15−17, respectively, in high
yields using mild copper-mediated conditions.18c,33 Similarly,
compound 13d could undergo eﬃcient Suzuki−Miyaura cross
coupling to furnish C7-arylated product 18 (Scheme 5).34
Another valuable transformation was the peroxide-mediated
oxidation of 7-borotryptophan 13f that delivered the
corresponding phenol 19 in 65% yield.35 Interestingly, aqueous
hydroxylamine in methanol also proved highly eﬃcient for this
oxidation, with these milder conditions providing compound
19 in 86% yield.36
In summary, we have described a direct, practical, and
scalable methodology for the one-pot conversion of C3-
alkylindoles to the corresponding C7-boronated derivatives.
The synthesis and study of a series of C2/C7-diboronated 3-
alkylindoles and development of conditions for C2-selective
protodeboronation of these C2/C7-diboronated indoles,
including tryptophan and tryptamine derivatives, was described
(Scheme 3, Table 1). The value of this strategy as an expedient
means for rapid C7 derivatization of C3-alkylindoles was
underscored by the gram-scale synthesis of C7-boronated N-
Boc-L-tryptophan methyl ester (Scheme 4), providing a rapid
entry to various unnatural amino acid derivatives (Scheme 5).
■ EXPERIMENTAL SECTION
General Methods. All reactions were performed in oven- or ﬂame-
dried round-bottomed ﬂasks, reinforced screw-capped pressure tubes,
or modiﬁed Schlenk (Kjeldahl shape) ﬂasks. The ﬂasks were ﬁtted with
rubber septa, and reactions were conducted under a positive pressure
of argon. Stainless steel syringes or cannulae were used to transfer air-
and moisture-sensitive liquids. Flash column chromatography was
performed as described by Still et al. using silica gel (60 Å pore size,
40−63 μm, 4−6% H2O content).37 Analytical thin-layer chromatog-
raphy was performed using glass plates precoated with 0.25 mm 230−
400 mesh silica gel impregnated with a ﬂuorescent indicator (254 nm).
Thin layer chromatography plates were visualized by exposure to
ultraviolet light and/or an aqueous solution of ceric ammonium
molybdate (CAM) followed by heating (<1 min) on a hot plate (∼250
°C). Unless otherwise stated, all chemicals and solvents were obtained
from commercial sources and used as received with the following
exceptions: dichloromethane, tetrahydrofuran, hexane, toluene,
methanol, and triethylamine were puriﬁed by the method of Grubbs
et al. under positive argon pressure.38 Proton (1H) and carbon (13C)
nuclear magnetic resonance spectra were recorded with 600, 500, and
400 MHz spectrometers. Proton nuclear magnetic resonance (1H
NMR) spectra are reported in parts per million on the δ scale and are
referenced from the residual protium in the NMR solvent (CDCl3, δ
7.24 (CHCl3); CD3OD, δ 3.31 (CH3OH)). Data is reported as
follows: chemical shift [multiplicity (s = singlet, d = doublet, t = triplet,
q = quartet, st = sextet, sp = septet, m = multiplet, app = apparent, br =
broad)], coupling constant(s) in hertz, integration. Carbon-13 nuclear
magnetic resonance (13C NMR) spectra are reported in parts per
million on the δ scale and are referenced from the carbon resonances
of the solvent (CDCl3, δ 77.23; CD3OD, δ 49.15). Assignments of
13C
chemical shifts for boron-bound carbons were not made owing to the
eﬀect of quadrupolar relaxation on the intensity of these signals.39 Data
is reported as follows: chemical shift. Infrared data (IR) were obtained
with a FTIR and are reported as follows: [frequency of absorption
(cm−1), intensity of absorption (s = strong, m = medium, w = weak, br
= broad)]. High-resolution mass spectrometric data (HRMS) were
recorded on a FT-ICR-MS spectrometer using electrospray ionization
(ESI) source or direct analysis in real-time (DART) ionization source.
N-(2-(1H-Indol-3-yl)ethyl)-N,2,4,6-tetramethylbenzenesulfo-
namide (11a). Triethylamine (1.80 mL, 12.9 mmol, 1.04 equiv) was
added via syringe to a solution of tryptamine (2.0 g, 12.4 mmol, 1
equiv) in dichloromethane (60 mL) at 23 °C under an argon
atmosphere. A sample of 2-mesitylenesulfonyl chloride (2.6 g, 11.9
mmol, 0.96 equiv) was added cautiously, resulting in a slight exotherm.
After 1 h, the reaction mixture was diluted with diethyl ether (500 mL)
and washed with distilled water (300 mL). The aqueous layer was
removed, and the organic layer was acidiﬁed to pH 1−2 by slow
addition of aqueous hydrochloric acid (1N, 600 mL). The organic
layer was washed with saturated aqueous sodium bicarbonate solution
(2 × 300 mL), dried over anhydrous sodium sulfate, ﬁltered, and
concentrated under reduced pressure. The residue was dissolved in
toluene and concentrated (2 × 100 mL) to give N-(2-(1H-indol-3-
yl)ethyl)-2,4,6-trimethylbenzenesulfonamide S1 as a yellow solid. This
material was suﬃciently clean to be used in the next step without
further puriﬁcation; mp 92−95 °C. 1H NMR (500 MHz, CDCl3, 20
°C): δ 8.15 (br s, 1H), 7.44−7.27 (m, 2H), 7.17 (dd, J = 7.5, 8.5 Hz,
1H), 7.02 (t, J = 7.5 Hz, 1H), 6.94 (d, J = 2.5 Hz, 1H), 6.83 (s, 2H),
4.51 (t, J = 6.0 Hz, 1H), 3.20 (q, J = 6.5 Hz, 2H), 2.92 (t, J = 6.5 Hz,
2H), 2.45 (s, 6H), 2.26 (s, 3H). 13C NMR (125 MHz, CDCl3, 20 °C):
δ 142.3, 139.2, 136.7, 133.5, 132.1, 127.0, 122.8, 122.5, 119.7, 118.6,
111.7, 111.5, 42.6, 25.5, 22.9, 21.1. FTIR (thin ﬁlm, cm−1): 3397 (br
s), 1604 (m), 1458 (s), 1317 (s), 1153 (s), 1076 (m), 744 (s), 656 (s).
HRMS (ESI, TOF) (m/z): calcd for C19H23N2O2S [M + H
+],
343.1475; found, 343.1466. TLC (30% ethyl acetate in hexanes), Rf =
0.36 (CAM, UV). The sulfonamide S1 was dissolved in
dimethylformamide (60 mL), and 1,8-diazabicyclo[5.4.0]undec-7-ene
(7.18 mL, 48.0 mmol, 3.87 equiv) was added. A sample of dimethyl
sulfate (2.88 mL, 30.0 mmol, 2.42 equiv) was added, and the reaction
mixture was stirred at 23 °C. After 3 h, another sample of 1,8-
diazabicyclo[5.4.0]undec-7-ene (7.18 mL, 48.0 mmol, 3.87 equiv) and
dimethyl sulfate (2.88 mL, 30.0 mmol, 2.42 equiv) was added. After 3
h, the reaction mixture was diluted with diethyl ether (200 mL) and
washed with aqueous hydrochloric acid (1N, 500 mL). The organic
layer was washed with saturated aqueous sodium bicarbonate solution
(2 × 300 mL) and brine (300 mL) and was dried over anhydrous
sodium sulfate. The organic layer was ﬁltered and concentrated under
reduced pressure, and the resulting brown residue was puriﬁed by ﬂash
column chromatography (silica gel, 4 cm × 8 cm; eluent, 50% ethyl
acetate in hexanes) to aﬀord N-methyl sulfamide 11a as an orange
powder (3.30 g, 77.3% over two steps); mp 104−105 °C. 1H NMR
(500 MHz, CDCl3, 20 °C): δ 8.03 (br s, 1H), 7.36 (d, J = 7.5 Hz, 1H),
7.32 (app dd, J = 0.5, 8.0 Hz, 1H), 7.15 (t, J = 8.0 Hz, 1H), 7.03 (t, J =
7.0 Hz, 1H), 6.94 (d, J = 2.0 Hz, 1H), 6.87 (s, 2H), 3.43−3.38 (m,
2H), 3.32−2.97 (m, 2H), 2.84 (s, 3H), 2.55 (s, 6H), 2.27 (s, 3H). 13C
NMR (125 MHz, CDCl3, 20 °C): δ 142.5, 140.5, 136.4, 132.4, 132.0,
127.3, 122.2, 122.1, 119.5, 118.6, 112.6, 111.3, 49.6, 33.1, 23.9, 22.9,
21.2. FTIR (thin ﬁlm, cm−1): 3403 (br s), 1604 (m), 1457 (s), 1309
(s), 1148 (s), 949 (s), 742 (s), 727 (s). HRMS (ESI, TOF) (m/z):
Scheme 5. Derivatization of 7-Tryptophansa
aConditions: (a) 13d, (i) for 15, CuCl2 2H2O, MeOH, H2O, 80 °C, 3
h, 93%; (ii) for 16, CuBr2, MeOH, H2O, 80 °C, 5 h, 76%; (b) 13d,
Cu2O, NaI, aq NH3/MeOH, 23 °C, 14 h, 85%; (c) 13f, (i) 30% aq
H2O2, 2% aq NaOH, THF, 23 °C, 30 min, 65%; (ii) 50% aq NH2OH,
MeOH, 23 °C, 21 h, 86%; (d) 13d, p-bromoanisole, SPhos, Pd2(dba)3,
K3PO4, PhMe, 80 °C, 12 h, 76%.
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calcd for C20H25N2O2S [M + H]
+, 357.1631; found, 357.1617. TLC
(30% ethyl acetate in hexanes), Rf = 0.49 (CAM, UV).
N-(2-(2,7-Bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
1H-indol-3-yl)ethyl)-N,2,4,6-tetra-methylbenzenesulfonamide
(12a). A round-bottomed ﬂask equipped with a stir bar was charged
sequentially with bis(pinacolato)diboron (142 mg, 560 μmol, 2.00
equiv), tryptamine 11a (100 mg, 281 μmol, 1 equiv), (1,5-
cyclooctadiene)(methoxy)iridium(I) dimer (3.7 mg, 5.6 μmol, 2.0
mol %), and 4,4′-di-tert-butyl-2,2′-bipyridine (3.0 mg, 11 μmol, 4.0
mol %). The ﬂask was placed under an argon atmosphere, anhydrous
tetrahydrofuran (1.4 mL) was added to the ﬂask, and the resulting
red−brown solution was stirred at 65 °C. After 20 h, the volatiles were
then removed under reduced pressure, and the resulting black residue
was puriﬁed by ﬂash column chromatography (eluent: 25% ethyl
acetate in hexanes) to aﬀord 12a as a white foamy solid (136 mg,
80.1%); mp 163.5−165 °C. 1H NMR (400 MHz, CDCl3, 20 °C): δ
9.06 (br s, 1H), 7.62 (dd, J = 1.0, 7.0 Hz, 1H), 7.36 (d, J = 8.0 Hz,
1H), 6.96 (t, J = 7.0 Hz, 1H), 6.72 (s, 2H), 3.27−3.20 (m, 2H), 3.19−
3.12 (m, 2H), 2.97 (s, 3H), 2.46 (s, 6H), 2.21 (s, 3H), 1.39 (s, 12H),
1.33 (s, 12H). 13C NMR (100 MHz, CDCl3, 20 °C): δ 143.1, 142.2,
140.4, 132.4, 131.8, 131.5, 127.0, 125.0, 122.9, 119.0, 84.0, 83.9, 50.6,
32.5, 25.2, 25.1, 23.4, 22.9, 21.2. FTIR (thin ﬁlm, cm−1): 3455 (m),
2978 (m), 2930 (m), 1598 (m), 1551 (m), 1372 (s), 1320 (s), 1292
(s), 1141 (s), 683 (m). HRMS (ESI, TOF) (m/z): calcd for
C32H47B2N2O6S [M + H]
+, 609.3360; found, 609.3371. TLC (20%
ethyl acetate in hexanes), Rf = 0.47 (CAM, UV).
N,2,4,6-Tetramethyl-N-(2-(7-(4,4,5,5-tetramethyl-1,3,2-diox-
aborolan-2-yl)-1H-indol-3-yl)ethyl)-benzenesulfonamide
(13a). A sample of diborotryptamine 12a (500.0 mg, 822 μmol, 1
equiv) in a 25 mL round-bottomed ﬂask was ﬂushed three times with
argon, then was dissolved in anhydrous dichloromethane (8.0 mL) and
cooled to 0 °C. Triﬂuoroacetic acid (0.620 mL, 8.34 mmol, 10.2
equiv) was then added dropwise via a gastight syringe, and the
colorless reaction solution was stirred at 0 °C for 5 min before
warming to 23 °C over 10 min. After a further 5 min, the resulting
light-green solution was concentrated under reduced pressure to leave
a pale-green residue, which was puriﬁed by ﬂash column
chromatography on silica gel (eluent: 20% ethyl acetate in hexanes)
to provide the boronic ester 13a as a white foamy solid (320 mg,
80.7%). Structural assignments were made with additional information
from gCOSY, HSQC, and gHMBC data; mp 44−44.5 °C. 1H NMR
(600 MHz, CDCl3, 20 °C): δ 9.03 (br s, 1H), 7.62 (d, J = 7.0 Hz, 1H),
7.47 (d, J = 7.8 Hz, 1H), 7.05 (app t, J = 7.3 Hz, 1H), 7.01 (d, J = 1.7
Hz, 1H), 6.86 (s, 2H), 3.39 (t, J = 7.7 Hz, 2H), 3.00 (t, J = 8.0 Hz,
2H), 2.85 (s, 3H), 2.55 (s, 6H), 2.27 (s, 3H), 1.38 (s, 12H). 13C NMR
(150 MHz, CDCl3, 20 °C): δ 142.4, 141.5, 140.3, 132.4, 131.9, 129.3,
126.0, 122.1, 122.0, 118.9, 112.0, 83.9, 49.7, 33.0, 25.1, 23.8, 22.9, 21.1.
FTIR (thin ﬁlm, cm−1): 3457 (s), 2978 (s), 2936 (s), 1605 (m), 1592
(m), 1372 (s), 1328 (s), 1151 (s), 729 (w). HRMS (ESI, TOF) (m/
z): calcd for C26H36BN2O4S [M + H]
+, 483.2498; found, 483.2488.




A round-bottomed ﬂask equipped with a stir bar was charged
sequentially with bis(pinacolato)diboron (71.1 mg, 280 μmol, 1.00
equiv), tryptamine 11a (100 mg, 280 μmol, 1 equiv), (1,5-
cyclooctadiene)(methoxy)iridium(I) dimer (3.7 mg, 5.6 μmol, 2.0
mol %), and 4,4′-di-tert-butyl-2,2′-bipyridine (3.0 mg, 11 mmol, 4.0
mol %). After ﬂushing with argon for 5 min, anhydrous dichloro-
methane (1.4 mL) was added to the ﬂask and the resulting red
solution was stirred at 60 °C. After 3 h, the volatiles were removed
under reduced pressure, and the resulting black residue was puriﬁed by
ﬂash column chromatography (eluent: 25% ethyl acetate in hexanes)
to aﬀord 14 as a white foamy solid (91.6 mg, 67.7%); mp 42−43 °C.
1H NMR (500 MHz, CDCl3, 20 °C): δ 8.34 (br s, 1H), 7.26 (t, J = 8.0
Hz, 2H), 7.16 (ddd, J = 1.0, 7.0, 8.0 Hz, 1H), 6.95 (ddd, J = 1.0, 7.0,
8.0 Hz, 1H), 6.74 (s, 2H), 3.32−3.27 (m, 2H), 3.21−3.17 (m, 2H),
2.98 (s, 3H), 2.49 (s, 6H), 2.21 (s, 3H), 1.33 (s, 12H). 13C NMR (125
MHz, CDCl3, 20 °C): δ 142.2, 140.3, 138.2, 132.3, 132.0, 131.8, 127.9,
125.2, 123.8, 119.4, 111.4, 84.0, 50.4, 32.5, 25.1, 23.4, 22.9, 21.2. FTIR
(thin ﬁlm, cm−1): 3395 (br m), 2975 (s), 1550 (s), 1315 (s), 1144 (s),
730 (s). HRMS (ESI, TOF) (m/z): calcd for C26H36BN2O4S [M +
H]+, 483.2498; found, 483.2490. TLC (30% ethyl acetate in hexanes),
Rf = 0.41 (CAM, UV).
N,2,4,6-Tetramethyl-N-(2-(7-(4,4,5,5-tetramethyl-1,3,2-diox-
aborolan-2-yl)-1H-indol-3-yl)ethyl)-benzenesulfonamide
(13a). A pressure tube was charged sequentially with (1,5-
cyclooctadiene)(methoxy)iridium(I) dimer (5.0 mg, 7.5 μmol, 2.5
mol %), 4,4′-di-tert-butyl-2,2′-bipyridine (4.0 mg, 15 μmol, 5.0 mol
%), and tryptamine 11a (107 mg, 300 μmol, 1 equiv). The contents of
the reaction vessel were kept under an argon atmosphere. Freshly
distilled anhydrous tetrahydrofuran (2 mL) was then introduced to the
ﬂask via a gastight syringe to aﬀord a dark-brown solution.
Pinacolborane (218 μL, 1.50 mmol, 5.00 equiv) was added in a single
portion via a gastight syringe to aﬀord a red solution. The pressure
tube was sealed and was stirred at 80 °C for 21 h and 15 min. The tube
was subsequently cooled to 0 °C, and anhydrous dichloromethane (3
mL) was added under an argon atmosphere. Triﬂuoroacetic acid (2
mL) was then added dropwise via a gastight syringe to aﬀord a clear-
orange solution. The solution was stirred at 0 °C for 10 min and was
then warmed to 23 °C and was stirred for 5 h and 15 min. The
resulting solution was diluted with dichloromethane (50 mL) and was
washed with saturated aqueous sodium bicarbonate solution (50 mL).
The organic layer was dried over anhydrous sodium sulfate, ﬁltered,
and concentrated under reduced pressure. The resulting brown residue
was puriﬁed by ﬂash column chromatography on silica gel (eluent: 5%
acetone, 15% dichloromethane, 80% hexanes) to provide the boronic
ester 13a (86.4 mg, 59.6%). All data was in accordance with that
obtained from the aforementioned protodeboronation of 12a.
Methyl (2-(7-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-
1H-indol-3-yl)ethyl)carbamate (13b). A pressure tube was charged
sequentially with (1,5-cyclooctadiene)(methoxy)iridium(I) dimer (5.0
mg, 7.5 μmol, 2.5 mol %), 4,4′-di-tert-butyl-2,2′-bipyridine (4.0 mg, 15
μmol, 5.0 mol %), and tryptamine methyl carbamate40 11b (67.0 mg,
307 μmol, 1 equiv). The contents of the reaction vessel were kept
under an argon atmosphere. Freshly distilled anhydrous tetrahydrofur-
an (2 mL) was introduced to the ﬂask via a gastight syringe to aﬀord a
dark-brown solution. Pinacolborane (218 μL, 1.50 mmol, 4.86 equiv)
was added in a single portion via a gastight syringe, at which point the
solution turned bright red. The pressure tube was sealed and the
reaction mixture stirred at 60 °C for 6 h and 15 min and then cooled
to 0 °C, whereupon anhydrous dichloromethane (3 mL) was added
under an argon atmosphere. Triﬂuoroacetic acid (2 mL) was then
added dropwise via a gastight syringe to aﬀord an orange solution. The
solution was stirred at 0 °C for 10 min and then warmed to 23 °C and
stirred for 2 h and 30 min. The solution was diluted with
dichloromethane (50 mL) and washed with saturated aqueous sodium
bicarbonate solution (50 mL). The organic layer was dried over
anhydrous sodium sulfate, ﬁltered, and concentrated under reduced
pressure. The resulting brown residue was puriﬁed by ﬂash column
chromatography on silica gel (eluent: 10% acetone, 20% dichloro-
methane, 70% hexanes) to provide the boronic ester 13b (70.0 mg,
66.2%) as a white waxy solid. Structural assignments were made with
additional information from gCOSY, HSQC, and gHMBC data; mp
138−140 °C. 1H NMR (600 MHz, CDCl3, 20 °C): δ 9.07 (br s, 1H),
7.71 (d, J = 7.8 Hz, 1H), 7.64 (d, J = 6.9 Hz, 1H), 7.13 (app t, J = 7.3
Hz, 1H), 7.09 (br s, 1H), 4.71 (br s, 1H), 3.63 (s, 3H), 3.49 (app q,
2H), 2.97 (app t, 2H), 1.37 (s, 12H). 13C NMR (150 MHz, CDCl3, 20
°C): δ 157.2, 141.7, 129.6, 126.3, 122.4, 122.2, 119.1, 112.4, 84.0, 52.2,
41.4, 25.9, 25.1. FTIR (thin ﬁlm, cm−1): 3451 (s), 2978 (s), 2939 (s),
1713 (s), 1522 (m), 1373 (m), 1135 (s), 966 (w), 684 (m). HRMS
(ESI, TOF) (m/z): calcd for C18H26BN2O4 [M + H]
+, 345.1994;
found, 345.1996. TLC (10% acetone, 20% dichloromethane, 70%
hexanes), Rf = 0.21 (CAM, UV).
3-Methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
1H-indole (13c). A pressure tube was charged sequentially with (1,5-
cyclooctadiene)(methoxy)iridium(I) dimer (5.0 mg, 7.5 μmol, 2.5 mol
%), 4,4′-di-tert-butyl-2,2′-bipyridine (4.0 mg, 15 μmol, 5.0 mol %), and
3-methylindole 11c (39.0 mg, 0.297 mmol, 1 equiv). The contents of
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the reaction vessel were kept under an argon atmosphere. Anhydrous
tetrahydrofuran (2 mL) was introduced to the ﬂask under an argon
atmosphere to aﬀord a clear - brown solution. Pinacolborane (218 μL,
1.50 mmol, 5.05 equiv) was added in a single portion via a gastight
syringe, the pressure tube was sealed, and the resulting red solution
was stirred at 60 °C. After 5 h and 30 min, the reaction contents were
cooled to 0 °C, and anhydrous dichloromethane (3 mL) was added
under an argon atmosphere. Triﬂuoroacetic acid (2 mL) was then
added dropwise via a gastight syringe to aﬀord an orange solution that
was stirred at 0 °C for 10 min and then warmed to 23 °C and stirred
for a further 3 h. The resulting solution was diluted with
dichloromethane (50 mL) and washed with saturated aqueous sodium
bicarbonate solution (50 mL). The organic layer was dried over
anhydrous sodium sulfate, ﬁltered, and concentrated under reduced
pressure to give a brown residue that was puriﬁed by ﬂash column
chromatography on silica gel (eluent: 1.5% acetone in hexanes) to
provide the boronic ester 13c (41.0 mg, 53.6%) as a white waxy solid.
Structural assignments were made with additional information from
gCOSY, HSQC, and gHMBC data; mp 46−47 °C. 1H NMR (600
MHz, CDCl3, 20 °C): δ 8.94 (br s, 1H), 7.69 (d, J = 7.9 Hz, 1H), 7.63
(d, J = 7.0 Hz, 1H), 7.11 (t, J = 7.2 Hz, 1H), 7.00 (d, J = 0.6 Hz, 1H),
2.33 (s, 3H), 1.37 (s, 12H). 13C NMR (150 MHz, CDCl3, 20 °C): δ
141.5, 129.2, 127.3, 122.5, 121.6, 118.7, 111.2, 83.9, 25.1, 9.8. FTIR
(thin ﬁlm, cm−1): 3462 (s), 2977 (s), 2923 (m), 1607 (m), 1592 (m),
1437 (m), 1371 (s), 1136 (s), 848 (m). HRMS (ESI, TOF) (m/z):
calcd for C15H21BNO2 [M + H]
+, 258.1673; found, 258.1668. TLC
(5% diethyl ether in hexanes), Rf = 0.26 (CAM, UV).
Alternative Procedure, 3-Methyl-7-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)-1H-indole (13c). Anhydrous tetrahydrofuran
(11 mL) was added via syringe to 3-methylindole 11c (201 mg, 1.53
mmol, 1 equiv), (1,5-cyclooctadiene)(methoxy)iridium(I) dimer (25.4
mg, 38.3 μmol, 2.50 mol %), and 4,4′-di-tert-butyl-2,2′-bipyridine
(20.6 mg, 76.6 μmol, 5.00 mol %) sealed in a ﬂame-dried round-
bottomed ﬂask under an argon atmosphere to result in a dark-brown
solution. Pinacolborane (1.10 mL, 7.66 mmol, 5.00 equiv) was
introduced in a single portion via a gastight syringe, and the resulting
red solution was stirred at 60 °C for 8 h. After cooling to 23 °C and
removal of volatiles under reduced pressure, the subsequent brown
residue was dissolved in acetic acid (4.0 mL) and palladium(II) acetate
(17.2 mg, 76.6 μmol, 5.00 mol %) was added and the resulting mixture
was stirred under argon at 30 °C. After 8 h, the mixture was cooled to
23 °C and was ﬁltered through Celite with ethyl acetate (150 mL) as
eluent. The ﬁltrate was washed with saturated aqueous sodium
bicarbonate solution (200 mL), and the organic layer was dried over
anhydrous sodium sulfate, ﬁltered, and concentrated under reduced
pressure. The resulting brown residue was puriﬁed by ﬂash column
chromatography on silica gel (eluent: 1.5% acetone in hexanes) to
provide the boronic ester 13c (228 mg, 57.9%) as a white waxy solid.




(13d). A pressure tube was charged sequentially with (1,5-
cyclooctadiene)(methoxy)-iridium(I) dimer (5.0 mg, 7.5 μmol, 2.5
mol %), 4,4′-di-tert-butyl-2,2′-bipyridine (4.0 mg, 15 μmol, 5.0 mol
%), and L-tryptophan methyl ester 11d (83.0 mg, 300 μmol, 1 equiv).
The contents of the reaction vessel were kept under an argon
atmosphere. Anhydrous tetrahydrofuran (2 mL) was introduced to the
ﬂask via a gastight syringe to aﬀord a clear dark-brown solution.
Pinacolborane (218 μL, 1.50 mmol, 5.00 equiv) was then added in a
single portion via a gastight syringe, the pressure tube was sealed, and
the resulting red solution was stirred at 60 °C. After 4 h, the tube was
subsequently cooled to 0 °C and anhydrous dichloromethane (3 mL)
was added via a gastight syringe. Triﬂuoroacetic acid (2 mL) was
added dropwise via a gastight syringe to aﬀord an orange solution that
was stirred at 0 °C for 10 min, then was warmed to 23 °C and was
stirred for a further 5 h and 15 min. The resulting solution was diluted
with dichloromethane (50 mL) and washed with saturated aqueous
sodium bicarbonate solution (50 mL). The organic layer was dried
over anhydrous sodium sulfate, ﬁltered, and concentrated under
reduced pressure. The resulting brown residue was puriﬁed by ﬂash
column chromatography on silica gel (eluent: 8% acetone, 30%
dichloromethane, 62% hexanes) to provide the boronic ester 13d (101
mg, 83.5%) as a white powder. Structural assignments were made with
additional information from gCOSY, HSQC, and gHMBC data; mp
151−152 °C. 1H NMR (600 MHz, CDCl3, 20 °C): δ 9.16 (br s, 1H),
7.65 (d, J = 8.4 Hz, 1H), 7.62 (d, J = 7.2 Hz, 1H), 7.13 (app t, J = 7.3
Hz, 1H), 7.05 (d, J = 1.7 Hz, 1H), 5.28 (d, J = 8.1 Hz, 1H), 4.68 (q, J
= 2.8 Hz, 1H), 3.66 (s, 3H), 3.64 (s, 3H), 3.30 (d, J = 4.7 Hz, 2H),
1.37 (s, 12H). 13C NMR (150 MHz, CDCl3, 20 °C): δ 172.6, 156.5,
141.3, 129.5, 126.5, 122.9, 122.2, 119.2, 109.3, 83.9, 54.5, 52.4, 52.3,
28.0, 25.0. FTIR (thin ﬁlm, cm−1): 3448 (s), 2979 (s), 2953 (m), 1722
(s), 1591 (m), 1516 (s), 1374 (m), 1329 (m), 1134 (s), 684 (w).
HRMS (ESI, TOF) (m/z): calcd for C20H28BN2O6 [M + H]
+,
403.2050; found, 403.2030. TLC (10% acetone, 20% dichloro-
methane, 70% hexanes), Rf = 0.19 (CAM, UV).
Alternative Procedure, (S)-Methyl 2-((methoxycarbonyl)-
amino)-3-(7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl))-1H-
indol-3-yl)propanoate (13d). Anhydrous tetrahydrofuran (6 mL)
was added to L-tryptophan methyl ester 11d (203 mg, 735 μmol, 1
equiv), (1,5-cyclooctadiene)(methoxy)iridium(I) dimer (12.2 mg, 18.4
μmol, 2.50 mol %), and 4,4′-di-tert-butyl-2,2′-bipyridine (9.8 mg, 37
μmol, 5.0 mol %) sealed in a ﬂame-dried round-bottomed ﬂask under
an argon atmosphere. Pinacolborane (530 μL, 3.68 mmol, 5.00 equiv)
was added to the resulting dark-brown solution in a single portion via a
gastight syringe, and the resulting red solution was stirred at 60 °C.
After 8 h, the mixture was allowed to cool to 23 °C and the volatiles
were removed under reduced pressure to give a brown residue. Acetic
acid (1.8 mL) and palladium(II) acetate (8.3 mg, 37 μmol, 5.0 mol %)
were added, and the resulting mixture was stirred under argon at 30
°C. After 18 h, the mixture was allowed to cool to 23 °C and ﬁltered
through Celite with ethyl acetate (100 mL) as eluent. The ﬁltrate was
washed with saturated aqueous sodium bicarbonate solution (150
mL), and the organic layer was dried over anhydrous sodium sulfate,
ﬁltered, and concentrated under reduced pressure. The resulting
brown residue was puriﬁed by ﬂash column chromatography on silica
gel (eluent: 8% acetone, 30% dichloromethane, 62% hexanes) to
provide the boronic ester 13d (213 mg, 72.3%) as a white powder. All
data for 13d was in accordance with that obtained from the previous
procedure.
2-(7-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indol-
3-yl)ethan-1-ol (13e). A pressure tube was charged sequentially with
(1,5-cyclooctadiene)(methoxy)iridium(I) dimer (20.4 mg, 30.7 μmol,
2.42 mol %), 4,4′-di-tert-butyl-2,2′-bipyridine (16.5 mg, 61.4 μmol,
4.84 mol %), and tryptophol 11e (205 mg, 1.27 mmol, 1 equiv). The
contents of the reaction vessel were kept under an argon atmosphere.
Freshly distilled anhydrous tetrahydrofuran (10 mL) was introduced
to the ﬂask via a gastight syringe to aﬀord a dark-brown solution.
Pinacolborane (895 mL, 6.17 mmol, 4.87 equiv) was added in a single
portion via a gastight syringe, at which point the solution turned bright
red. The pressure tube was sealed and the reaction mixture was stirred
at 60 °C for 7 h, then cooled to 0 °C, whereupon anhydrous
dichloromethane (15 mL) was added under an argon atmosphere.
Triﬂuoroacetic acid (10 mL) was then added dropwise via a gastight
syringe to aﬀord an orange solution. The solution was stirred at 0 °C
for 10 min and was then warmed to 23 °C and was stirred for 4 h. The
reaction solution was diluted with dichloromethane (100 mL) and was
washed with saturated aqueous sodium bicarbonate solution (2 × 200
mL). The organic layer was concentrated under reduced pressure,
dissolved in pentane/diethyl ether (2:1, 300 mL), and washed with
water (5 × 300 mL). The organic layer was dried over anhydrous
sodium sulfate, ﬁltered, and concentrated under reduced pressure to
leave a yellow residue that was puriﬁed by ﬂash column
chromatography on silica gel (eluent: 15% ethyl acetate in hexanes)
to give a white solid. This material was vacuum-dried (6−8 mTorr) for
48 h at 70 °C to remove remaining pinacol, and 7-borotryptophol 13e
was obtained as a white solid (227 mg, 62.7%); mp 78−78.5 °C. 1H
NMR (500 MHz, CDCl3, 20 °C): δ 9.12 (br s, 1H), 7.75 (d, J = 7.8
Hz, 1H), 7.67 (d, J = 7.0 Hz, 1H), 7.15 (t, J = 7.4 Hz, 1H), 7.13 (s,
1H), 3.92−3.86 (m, 2H), 3.05 (t, J = 6.2 Hz, 2H), 1.73 (br s, 1H),
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1.40 (s, 12H). 13C NMR (125 MHz, CDCl3, 20 °C): δ 142.3, 130.2,
127.0, 123.2, 123.1, 119.7, 112.3, 84.5, 63.4, 29.5, 25.7. FTIR (thin
ﬁlm, cm−1): 3457 (br), 2978 (s), 1684 (s), 1559 (m), 1437 (m), 1374
(w), 1329 (w), 1135 (w), 1048 (s), 668 (m). HRMS (ESI, TOF) (m/
z): calcd for C16H23BNO3 [M + H]
+, 288.1766; found, 288.1763. TLC
(30% ethyl acetate in hexanes), Rf = 0.24 (CAM, UV).
(S)-Methyl 2-((tert-Butoxycarbonyl)amino)-3-(7-(4,4,5,5-tet-
ramethyl-1,3,2-dioxaborolan-2-yl)-1H-indol-3-yl)propanoate
(13f). N-Boc-L-tryptophan methyl ester 11f (1.01 g, 3.18 mmol, 1
equiv), (1,5-cyclooctadiene)(methoxy)iridium(I) dimer (52.8 mg, 79.6
μmol, 2.50 mol %), and 4,4′-di-tert-butyl-2,2′-bipyridine (42.7 mg, 159
μmol, 5.00 mol %) were sealed in a ﬂame-dried round-bottomed ﬂask
under an argon atmosphere and anhydrous tetrahydrofuran (32 mL)
was added. To the resulting dark-brown solution was added
pinacolborane (2.31 mL, 15.9 mmol, 5.00 equiv) in a single portion
via a gastight syringe, and the resulting red solution was stirred at 60
°C for 12 h. After cooling to 23 °C and removal of volatiles under
reduced pressure, the subsequent brown residue was dissolved in
acetic acid (3.5 mL) and palladium(II) acetate (35.7 mg, 0.159 mmol,
5.00 mol %) was added. The mixture was stirred under argon at 30 °C
for 10 h, then cooled to 23 °C and ﬁltered through Celite with ethyl
acetate (50 mL) as eluent. The ﬁltrate was washed with saturated
aqueous sodium bicarbonate solution (50 mL), and the organic layer
was dried over anhydrous sodium sulfate, ﬁltered, and concentrated
under reduced pressure. The resulting brown residue was puriﬁed by
ﬂash column chromatography on silica gel (eluent: 5% acetone, 15%
dichloromethane, 80% hexanes) to provide the 7-borotryptophan
derivative 13f as a white powder (1.03 g, 73.1%); mp 152−153 °C. 1H
NMR (500 MHz, CDCl3, 20 °C): δ 9.11 (br s, 1H), 7.65 (d, J = 8.0
Hz, 1H), 7.62 (d, J = 7.0 Hz, 1H), 7.11 (t, J = 7.5 Hz, 1H), 7.04 (s,
1H), 5.03 (d, J = 8.0 Hz, 1H), 4.65−4.57 (m, 1H), 3.65 (s, 3H), 3.29
(d, J = 5.0 Hz, 2H), 1.41 (s, 9H), 1.37 (s, 12H). 13C NMR (125 MHz,
CDCl3, 20 °C): δ 172.9, 155.4, 141.5, 129.7, 126.8, 122.9, 122.5, 119.3,
109.8, 84.0, 79.9, 54.4, 52.4, 28.5, 28.1, 25.2. FTIR (thin ﬁlm, cm−1):
3451 (br s), 2978 (m), 1745 (s), 1714 (s), 1592 (m), 1493 (s), 1436
(m), 1373 (m), 1329 (m), 1167 (m), 1134 (s), 1050 (m), 966 (s), 914
(s), 849 (m). HRMS (ESI, TOF) (m/z): calcd for C23H34BN2O6 [M +
H]+, 445.2520; found, 445.2515. Anal. Calcd for C23H33BN2O6: C,
62.17; H, 7.49; N, 6.30. Found: C, 62.24; H, 7.42; N, 6.24. TLC (5%
acetone, 15% dichloromethane, 80% hexanes), Rf = 0.28 (CAM, UV).
(S)-Methyl 2-((Methoxycarbonyl)amino)-3-(7-chloro-1H-
indol-3-yl)propanoate (15). To a methanol solution (2.4 mL) of
7-borotryptophan 13d (80.5 mg, 200 μmol, 1 equiv) was added an
aqueous solution (2.4 mL) of copper(II) chloride dihydrate (102 mg,
670 μmol, 3.35 equiv). The resulting mixture was stirred for 3 h at 80
°C, then cooled to 23 °C and diluted with ethyl acetate (10 mL). The
organic layer was separated, and the aqueous layer was extracted with
ethyl acetate (2 × 20 mL). The combined organic layers were washed
with brine, dried over anhydrous sodium sulfate, ﬁltered, and
concentrated under reduced pressure. The resulting residue was
puriﬁed by ﬂash column chromatography on silica gel (eluent: 25%
ethyl acetate in hexanes) to provide tryptophan 15 as white needles
(57.7 mg, 92.7% yield); mp 118.5−119 °C. 1H NMR (500 MHz,
CDCl3, 20 °C): δ 8.33 (br s, 1H), 7.42 (d, J = 8.0 Hz, 1H), 7.17 (d, J =
7.0 Hz, 1H), 7.08−7.01 (m, 2H), 5.22 (d, J = 7.5 Hz, 1H), 4.72−4.64
(m, 1H), 3.66 (s, 3H), 3.65 (s, 3H), 3.27 (d, J = 5.0 Hz, 2H). 13C
NMR (125 MHz, CDCl3, 20 °C): δ 172.5, 156.6, 133.6, 129.2, 123.6,
121.9, 120.7, 117.5, 117.0, 111.4, 54.6, 52.63, 52.57, 28.3. FTIR (thin
ﬁlm, cm−1): 3341 (br s), 2952 (s), 1709 (s), 1521 (m), 1439 (s), 1341
(m), 1205 (m), 1082 (m), 895 (s), 843 (s), 779 (s), 738 (s). HRMS
(ESI, TOF) (m/z): calcd for C14H16ClN2O4 [M + H]
+, 311.0793;
found, 311.0808. TLC (25% ethyl acetate in hexanes), Rf = 0.17
(CAM, UV).
(S)-Methyl 2-((Methoxycarbonyl)amino)-3-(7-bromo-1H-
indol-3-yl)propanoate (16). To a methanol solution (2.4 mL) of
7-borotryptophan 13d (80.5 mg, 200 μmol, 1 equiv) was added an
aqueous solution (2.4 mL) of copper(II) bromide (134 mg, 600 μmol,
3.00 equiv). The resulting mixture was heated at 80 °C for 4 h and 30
min. The reaction mixture was cooled to 23 °C and was diluted with
ethyl acetate (10 mL). The organic layer was separated, and the
aqueous layer was extracted with ethyl acetate (2 × 10 mL). The
combined organic layers were washed with brine, dried over anhydrous
sodium sulfate, ﬁltered, and concentrated under reduced pressure. The
resulting residue was puriﬁed by ﬂash column chromatography on
silica gel (eluent: 25% ethyl acetate in hexanes) to provide tryptophan
16 as a light-yellow powder (54.2 mg, 76.2% yield); mp 123−124 °C.
1H NMR (500 MHz, CDCl3, 20 °C): δ 8.30 (br s, 1H), 7.46 (d, J = 7.5
Hz, 1H), 7.32 (d, J = 7.5 Hz, 1H), 7.04 (d, J = 1.0 Hz, 1H), 6.99 (t, J =
8.0 Hz, 1H), 5.23 (d, J = 8.0 Hz, 1H), 4.72−4.64 (m, 1H), 3.66 (s,
3H), 3.65 (s, 3H), 3.26 (d, J = 5.0 Hz, 2H). 13C NMR (125 MHz,
CDCl3, 20 °C): δ 172.5, 156.6, 135.0, 128.9, 124.8, 123.6, 121.1, 118.1,
111.5, 105.1, 54.6, 52.64, 52.57, 28.4. FTIR (thin ﬁlm, cm−1): 3335 (br
s), 2952 (s), 1707 (s), 1521 (m), 1437 (s), 1337 (m), 1203 (m), 1077
(m), 882 (s), 827 (s), 777 (s), 738 (s). HRMS (ESI, TOF) (m/z):
calcd for C14H16BrN2O4 [M + H]
+, 355.0288; found, 355.0281. TLC
(25% ethyl acetate in hexanes), Rf = 0.17 (CAM, UV).
(S)-Methyl 2-((Methoxycarbonyl)amino)-3-(7-iodo-1H-indol-
3-yl)propanoate (17). A round bottomed ﬂask was charged with
copper(I) oxide (2.9 mg, 20 μmol, 10 mol %) and 28% aqueous
ammonia (62 μL, 500 μmol, 2.5 equiv), and the resulting mixture was
stirred under air at 23 °C for 15 min. 7-Borotryptophan 13d (80.5 mg,
200 μmol, 1 equiv), sodium iodide (150 mg, 1.00 mmol, 5.00 equiv),
and methanol (0.6 mL) were then added to the reaction solution, and
stirring under air was continued at 23 °C for 14 h. The resulting
solution was concentrated under reduced pressure, and the residue was
dissolved in water (5 mL). This aqueous solution was then extracted
with ethyl acetate (3 × 20 mL), and the combined organic layers were
dried over anhydrous sodium sulfate, ﬁltered, and concentrated under
reduced pressure. The resulting residue was puriﬁed by ﬂash column
chromatography on silica gel (eluent: 25% ethyl acetate in hexanes) to
provide tryptophan 17 as a white solid (68.5 mg, 85.1% yield); mp
119−119.5 °C. 1H NMR (500 MHz, CDCl3, 20 °C): δ 8.13 (br s,
1H), 7.53 (d, J = 7.5 Hz, 1H), 7.49 (d, J = 8.0 Hz, 1H), 7.05 (d, J = 2.0
Hz, 1H), 6.88 (t, J = 8.0 Hz, 1H), 5.19 (d, J = 8.0 Hz, 1H), 4.71−4.65
(m, 1H), 3.66 (s, 3H), 3.65 (s, 3H), 3.25 (d, J = 5.5 Hz, 2H). 13C
NMR (125 MHz, CDCl3, 20 °C): δ 172.5, 156.6, 138.1, 131.1, 127.8,
123.3, 121.6, 119.0, 111.8, 54.5, 52.64, 52.57, 28.5. FTIR (thin ﬁlm,
cm−1): 3464 (br s), 1708 (s), 1517 (m), 1432 (s), 1333 (m), 1202
(m), 1075 (m), 776 (s), 666 (s). HRMS (ESI, TOF) (m/z): calcd for
C14H16IN2O4 [M + H]
+, 403.0149; found, 403.0151. TLC (25% ethyl
acetate in hexanes), Rf = 0.14 (CAM, UV).
(S)-Methyl 2-((Methoxycarbonyl)amino)-3-(7-(4-methoxy-
phenyl)-1H-indol-3-yl)propanoate (18). A dry round-bottomed
ﬂask was charged sequentially with 7-borotryptophan 13d (80.5 mg,
200 μmol, 1 equiv), tris(dibenzylideneacetone)dipalladium(0) (9.1
mg, 10 μmol, 5.0 mol %), SPhos (8.2 mg, 20 μmol, 10 mol %), and
tribasic potassium phosphate (84.9 mg, 400 μmol, 2.00 equiv), sealed,
and placed under an argon atmosphere. Toluene (0.8 mL) was added,
and to the resulting red−brown slurry p-bromoanisole (30.0 μL, 239
μmol, 1.20 equiv) was added via syringe in a single portion. The
resulting dark-green reaction mixture was stirred at 80 °C for 12 h,
then was cooled to 23 °C and ﬁltered through Celite with ethyl acetate
as eluent. The ﬁltrate was concentrated under reduced pressure to
yield a residue that was puriﬁed by ﬂash column chromatography on
silica gel (eluent: 40% ethyl acetate in hexanes) to provide tryptophan
18 as a white waxy solid (58.5 mg, 76.4% yield); mp 165 °C
(decomp.). 1H NMR (400 MHz, CDCl3, 20 °C): δ 8.26 (br s, 1H),
7.52 (d, J = 8.5 Hz, 2H), 7.49 (dd, J = 7.3 Hz, 1.3 Hz, 1H), 7.20−7.14
(m, 2H), 7.02 (d, J = 9.0 Hz, 2H), 6.99 (s, 1H), 5.24 (d, J = 7.5 Hz,
1H), 4.74−4.67 (m, 1H), 3.86 (s, 3H), 3.69 (s, 3H), 3.65 (s, 3H), 3.31
(d, J = 5.5 Hz, 2H). 13C NMR (125 MHz, CDCl3, 20 °C): δ 172.7,
159.3, 156.7, 134.3, 131.5, 129.5, 128.1, 125.7, 123.1, 122.2, 120.5,
117.6, 114.8, 110.6, 55.6, 54.7, 52.6, 52.5, 28.2. FTIR (thin ﬁlm, cm−1):
3374 (br s), 2952 (s), 1710 (s), 1610 (s), 1513 (s), 1438 (m), 1355
(m), 1247 (m), 1056 (s), 1029 (s), 836 (s), 799 (m), 748 (s). HRMS
(ESI, TOF) (m/z): calcd for C21H23N2O5 [M + H]
+, 383.1601; found,
383.1617. TLC (40% ethyl acetate in hexanes), Rf = 0.29 (CAM, UV).
(S)-Methyl 2-((tert-Butoxycarbonyl)amino)-3-(7-hydroxy-1H-
indol-3-yl)propanoate (19). Conditions: (i) A sample of N-Boc
tryptophan boronic ester 13f (20.2 mg, 45.5 μmol, 1 equiv) was
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dissolved in anhydrous tetrahydrofuran (0.5 mL) and a solution of 2%
aqueous sodium hydroxide was added (0.5 mL), followed by slow
addition of 30% (wt) aqueous hydrogen peroxide (51.5 μL, 455 μmol,
10.0 equiv). The resulting purple reaction solution was stirred for 30
min at 23 °C and then quenched by addition of a solution of saturated
ammonium hydroxide/saturated ammonium chloride (3:1, 5 mL).
After extracting with ethyl acetate (3 × 5 mL), the organic layers were
combined and washed with brine (2 × 10 mL), dried over anhydrous
sodium sulfate, ﬁltered, and concentrated under reduced pressure. The
resulting brown residue was puriﬁed by ﬂash column chromatography
on silica gel (eluent: 15% acetone, 15% dichloromethane, 70%
hexanes) to aﬀord phenol 19 as an oﬀ-white solid (9.8 mg, 64.6%). (ii)
To a sample of N-Boc tryptophan boronic ester 13f (25.3 mg, 56.9
μmol, 1 equiv) in methanol (1.0 mL) was added 50% aqueous
hydroxylamine (18.8 μL, 285 μmol, 5.00 equiv), and the resulting
white slurry was stirred at 23 °C. After 3 h, another dose of 50%
aqueous hydroxylamine (18.8 mg, 285 μmol, 5.00 equiv) was added
and the reaction was stirred at 23 °C. After 15 h, the reaction mixture
had turned into a light-brown solution, at which time TLC analysis
indicated complete disappearance of starting material. The reaction
was diluted with water (5 mL) and was extracted with ethyl acetate (3
× 5 mL). The organic layers were combined and were washed
sequentially with saturated aqueous ammonium chloride (2 × 10 mL),
saturated aqueous sodium bicarbonate (10 mL), and brine (10 mL)
before being dried over anhydrous sodium sulfate. After ﬁltration and
concentration under reduced pressure, the resulting brown residue was
puriﬁed by ﬂash column chromatography on silica gel (eluent: 15%
acetone, 15% dichloromethane, 70% hexanes) to aﬀord phenol 19 as
an oﬀ-white powder (16.8 mg, 86.3%); mp 185 °C (decomp.). 1H
NMR (500 MHz, CD3OD, 20 °C): δ 7.02 (d, J = 7.0 Hz, 1H), 7.01 (s,
1H), 6.83 (t, J = 7.6 Hz, 1H), 6.51 (d, J = 7.6 Hz, 1H), 4.40−4.37 (m,
1H), 3.65 (s, 3H), 3.20 (d, J = 14.5, 5.5 Hz, 1H), 3.08 (d, J = 14.5, 8.2
Hz, 1H), 1.39 (s, 9H). 13C NMR (125 MHz, CDCl3, 20 °C): δ 174.9,
157.9, 144.8, 130.9, 128.1, 124.1, 120.7, 111.3, 111.0, 106.8, 80.8, 56.3,
52.7, 29.0, 28.8. FTIR (thin ﬁlm, cm−1): 3384 (br), 2899 (m), 1684
(s), 1583 (m), 1506 (m), 1437 (w), 1368 (m), 1164 (m). HRMS
(ESI, TOF) (m/z): calcd for C17H23N2O5 [M + H]
+, 335.1601; found,
335.1614. TLC (15% acetone, 15% dichloromethane, 70% hexanes),
Rf = 0.17 (CAM, UV).
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Fernańdez, R.; Lassaletta, J. M. Angew. Chem., Int. Ed. 2011, 50, 11724.
(f) Roosen, P. C.; Kallepalli, V. A.; Chattopadhyay, B.; Singleton, D.
The Journal of Organic Chemistry Note
dx.doi.org/10.1021/jo502062z | J. Org. Chem. 2014, 79, 11254−1126311262
A.; Maleczka, R. E., Jr.; Smith, M. R., III. J. Am. Chem. Soc. 2012, 134,
11350. (g) Sasaki, I.; Doi, H.; Hashimoto, T.; Kikuchi, T.; Ito, H.;
Ishiyama, T. Chem. Commun. 2013, 49, 7546. (h) Ros, A.; Fernańdez,
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